AREV NANOTEC BRANDS INC. (CSE:AREV) (OTC:AREVF) (CNSX:AREV.CN) (“AREV Nanotec”), is pleased to announce that AREV is utilizing its proprietary extraction technologies and facilitating initial efforts to identify broad spectrum antiviral agents derived from medicinal photochemistry sources including bioactive compounds sourced from Moringa oleifera and Moringa ovalifolia, identified in peer-reviewed publications as presenting a wide range of antiviral activity, and may demonstrate high affinity with viral protease inhibition.

In response to the CoVid19 pandemic AREV is pursuing collaborations with a number of world renowned University centers to facilitate advanced extraction of potential antiviral phytochemicals from medicinal plant libraries for screening specific small molecules that may be used to develop drugs against COVID-19 and other pandemic viral pathogens” said Mike Withrow, CEO, AREV Nanotec . “The work AREV already is doing for raw material sourcing in the natural products industry has allowed the evolution of corporate expertise to now become relevant for advancing discoveries in medicinal photochemistry”  

AREV’s current efforts to secure the antiviral characteristics of COvid19’s Mpro which remains as the important drug target against COVID-19 infection, will involve grant solicitation from funding sources for pre-clinical discover include NSF’s Rapid Response Research (RAPID) program to mobilize funding for high priority projects and the NIH Consortium for Advancing Research on Botanical and Other Natural Products (CARBON) Program, working with the National Center for Complementary and Integrative Health (NCCIH) as well as the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership and Biomedical Advanced Research and Development Authority (BARDA) to address the COVID-19 pandemic that are directing requests for proposals to numerous biopharmaceutical companies.

More than 2,100 plant species globally have the potential for being used as medical plants and it has been estimated, that plant derived drugs constitute as much as 25% of the total therapeutics while in fast developing countries such as India and China, the contribution is as much as 80%. 

Dr Roscoe M. Moore, Jr., DVM, MPH, PhD, Frmr US Assist. Surgeon General (retired), former Epidemic Intelligence Service Officer (EIS) at the Centers for Disease Control and Prevention (CDC) and a Board member of the Global Virus Network at the Institute of Human Virology, University of Maryland Medical Center stated “this initiative with AREV Nanotechnologies to secure molecular docking studies in-silico evaluations which identify indicated drug-likeness properties towards target protein from medicinal plants for inhibitors of COVID-19 main protease (Mpro), a potential drug target are being designed and promise to afford enormous opportunity for new therapeutic discovery”

The Company is not making any express or implied claims that it has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

The company has issued 350,000 stock options to Directors, Officers and Consultants of the Company at a price of $0.39 for a period of 5 years from the issued date. These options will vest immediately.

For further information, contact Mike Withrow, This email address is being protected from spambots. You need JavaScript enabled to view it. 778-929-6536. For more information visit arevnanotec.com

On behalf of the Board,

Mike Withrow
CEO & Director

About AREV NanoTec Inc.  
AREV NanoTec Brands Inc. (“AREV”) is an early stage publicly traded life science development enterprise focused on phytomedicinal extraction of novel therapeutic approaches to infectious diseases and subsequent comorbidities via its proprietary extraction systems to identify promising small molecules that present novel mechanisms of action in human and veterinary science.  

AREV’s model is to toll process extraction of targeted essential and functional oils and license its formulations to Licensed Producers in Canada.  The company utilizes toll processors in foreign countries to encapsulate and package its formulations that can be sold in traditional distribution channels and online.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements.  Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.